This past weekend Esperion participated, for the 15th year, in the American Heart Association’s (AHA) annual Heart Walk to raise money for cardiovascular disease research. It is hard for me to put into words the inspiring nature of these events – as patients, survivors, doctors and others join together to combat what continues to be the leading cause of death in the U.S.
This year’s AHA theme is “Why?” – fitting as of late I’ve been reflecting on my personal “why.” That is, why devote my time and effort to developing ETC-1002 to treat patients with high LDL-cholesterol, the number one modifiable risk factor for cardiovascular disease?
For me, my “why” is my father. Unfortunately, he died from a heart attack on January 7th, 1981 – almost 35 years ago – at a very young age. He was 48. I was only 20 – an age far too young to lose your father to a disease that continues to take the lives of our loved ones. In fact, I would venture to say most of you reading this blog have been affected by cardiovascular disease, either in your own families or through your friends. While our risk of dying from cardiovascular disease today is 60 percent less than it was more than 30 years ago when my father died, I believe the risk or dying from cardiovascular disease is still far too high – and my colleagues couldn’t agree more.
We here at Esperion believe we can help reduce this risk and improve the lives of millions of patients by doing what we do best: focusing the expertise, experience and prior successes of our team on the development of new LDL-cholesterol lowering therapies.
ETC-1002 has demonstrated significant and consistent reductions in LDL-cholesterol of between 30 and 40 percent as monotherapy; in combination with ezetimibe, LDL-cholesterol lowering of nearly 50 percent; and, in combination with statins, reduced LDL-cholesterol of more than 60 percent. Additionally, ETC-1002 has shown consistent hsCRP lowering of 30 – 40 percent even on top of a statin.
A drug like this can’t help but make a difference in the lives of millions of patients, and remains the reason why we work every day to rapidly advance ETC-1002 through development and approval.
I’d love to hear the “Why” that’s driving you to do what you do. Leave your thoughts in the comments below!